Potentiating the Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor Pathway

Dual Targeting of the Akt/mTOR Signaling Pathway Inhibits Castration-Resistant Prostate Cancer in a Genetically Engineered Mouse Model

(2012) N. Floc'h et al.   CANCER RESEARCH

Targeting the Insulin-like Growth Factor Axis for the Development of Novel Therapeutics in Oncology

(2012) J. Gao et al.   CANCER RESEARCH

Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators

(2012) Akihiro Fujimoto et al.   NATURE GENETICS

Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma

(2012) Cécile Guichard et al.   NATURE GENETICS

Combination of PI3K/mTOR Inhibitors: Antitumor Activity and Molecular Correlates

(2011) M. Mazzoletti et al.   CANCER RESEARCH

DNA Damage Response and Growth Factor Signaling Pathways in Gliomagenesis and Therapeutic Resistance

(2011) M. Squatrito et al.   CANCER RESEARCH

Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma

(2011) Wei-Tien Tai et al.   JOURNAL OF HEPATOLOGY

Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling

(2011) C Garofalo et al.   ONCOGENE

Tumor Suppressor CHK2: Regulator of DNA Damage Response and Mediator of Chromosomal Stability

(2010) A. Stolz et al.   CLINICAL CANCER RESEARCH

Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives

(2010) Ying-Chun Shen et al.   JOURNAL OF GASTROENTEROLOGY

IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage

(2010) Victoria Tovar et al.   JOURNAL OF HEPATOLOGY

A Kinase-Independent Role for Unoccupied Insulin and IGF-1 Receptors in the Control of Apoptosis

(2010) J. Boucher et al.   Science Signaling

Induction of Bim Expression Contributes to the Antitumor Synergy Between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular Carcinoma

(2009) D.-L. Ou et al.   CLINICAL CANCER RESEARCH

Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma

(2009) C. Desbois-Mouthon et al.   CLINICAL CANCER RESEARCH

Down-regulation of Phospho-Akt Is a Major Molecular Determinant of Bortezomib-Induced Apoptosis in Hepatocellular Carcinoma Cells

(2008) K.-F. Chen et al.   CANCER RESEARCH

Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis

(2008) Tanja Nussbaum et al.   HEPATOLOGY

Molecular targeted therapies in hepatocellular carcinoma

(2008) Josep M. Llovet et al.   HEPATOLOGY

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE